KATO III

KATO III/KATO III细胞系/KATO III细胞株/KATO III人胃腺癌细胞(低分化

Cell line name KATO III

Synonyms Kato III; Kato-III; KATO-III; KATOIII; KatoIII; KATO 3; JTC-28; Japanese Tissue Culture-28

Accession CVCL_0371

Resource Identification Initiative To cite this cell line use: KATO III (RRID:CVCL_0371)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).

Part of: MD Anderson Cell Lines Project.

Population: Japanese.

Doubling time: 36 hours (PubMed=209229); 32-34 hours (PubMed=3962675); 36 hours (PubMed=29435981); 37-41 hours (CelloPub=CLPUB00584); 1.5 days (Note=Lot 06302003), 32 hours (Note=Lot 05232008) (JCRB=JCRB0611).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: ChIP-seq GATA4 analysis.

Omics: ChIP-seq GATA6 analysis.

Omics: ChIP-seq KLF5 analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

 

PubMed=9247707; DOI=10.1080/15216549700202901

Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.

Expression of bone morphogenetic proteins of human neoplastic epithelial cells.

Biochem. Mol. Biol. Int. 42:497-505(1997)

 

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

 

PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x

Yokozaki H.

Molecular characteristics of eight gastric cancer cell lines established in Japan.

Pathol. Int. 50:767-777(2000)

 

PubMed=11314020; DOI=10.1038/sj.onc.1204160

Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T., Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.

Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1.

Oncogene 20:869-873(2001)

 

PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020

Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., Inazawa J.

Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.

Cancer Sci. 96:100-110(2005)

 

PubMed=17505008; DOI=10.1158/1078-0432.CCR-06-2743

Takeda M., Arao T., Yokote H., Komatsu T., Yanagihara K., Sasaki H., Yamada Y., Tamura T., Fukuoka K., Kimura H., Saijo N., Nishio K.

AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.

Clin. Cancer Res. 13:3051-3057(2007)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)